Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received Phase 1/2a IND approval from the U.S ...

The US Food and Drug Administration (FDA) has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC), a form of liver cancer. This is the second ...

Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, RNA editing gene therapy product for the ...

Per Charles River’s management, the tie-up, which will utilize its CDMO capabilities, is expected to bring the RZ-001, a potentially curative therapy, to HCC patients. Rznomics’ management ...

Rznomics raised KRW 20.3 bn ($16.5m) in pre-IPO funding in January, bringing its total raised capital to around $58m. The company said the partnership with Lilly is part of its strategy to ...

SEONGNAM, South Korea, May 19, 2023 /PRNewswire/ -- Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, recently received ...